In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study’s findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.
Potential Non-Invasive Alternatives to Self-Monitoring Devices
Home Care Management of Diabetes
Overcoming the Challenges of Diabetes: Talking With an 'Amazing Race' Winner
Hypoglycemia on a Clinically Relevant Level
Practice vs. Accountability in Diabetes Care
Shaping Diabetes Management With Digital Technology and Genomics
New Experimental Treatments for Diabetic Wounds
Catering Drug Therapies To Specific Subsets of Patients with Type 2 Diabetes
Optimizing Athletic Performance in Type 1 Diabetes
Structured Self-Monitoring of Blood Glucose
The Key to Successful Adherence to Diabetes Drug Regimens
The Potential of Statins to Prevent Diabetic-Related Blindness
The Impact of Race and Ethnicity on Insulin Regimens
Using Video Games to Improve Children’s Diets
The Treatment of Transplant Patients With Diabetes
Meal Time Interventions for Patients with Type 2 Diabetes
The Value of Behavior Change in Diabetes, for Patients and Professionals
New Guidelines for Exercise and Type 2 Diabetes
Use of Glucagon and Insulin in a Closed-Loop System
Changes in Diabetes Care
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video